<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924208</url>
  </required_header>
  <id_info>
    <org_study_id>Tons2</org_study_id>
    <nct_id>NCT01924208</nct_id>
  </id_info>
  <brief_title>Tonsillar Cytokine Expression After Allergen and/or Virus Intervention</brief_title>
  <acronym>Tons2</acronym>
  <official_title>T Cell and Interferon Expression in Tonsils After Sublingual Immunotherapy and/or Nasal Live Attenuated Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sigrid Juselius Foundation, Helsinki, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation for Paediatric Research, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EVO special government transfers, Turku, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotheses

        1. Immunotherapy induces tolerogenic effects to allergens in T cell regulation in tonsils.

        2. Influenza vaccination induces a strong interferon response and decreases Th2 response in
           tonsils.

        3. Influenza vaccination as an adjuvant on immunotherapy induces a better response to
           immunotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Tonsils are the primary nasopharyngeal lymphoid tissue and constitute the first
      contact point of the immune system to allergens and infectious agents. A peripheral T cell
      repertoire exists in tonsils, and tonsils have an active role for inducing and maintaining
      peripheral tolerance to allergens. Intralymphatic immunotherapy is a promising alternative
      for a subcutaneous or sublingual immunotherapy. More data is needed on the interaction
      between the peripheral (tonsillar) T cell response and specific allergen exposure and impact
      of respiratory virus infections on tolerance induction. Objective: To study the effects of
      sublingual grass pollen immunotherapy and/or nasal live attenuated influenza vaccine on
      tonsillar T cell and interferon (IFN) expression. In addition, we collect material on the
      investigation of role of tissues in immune tolerance and chronicity in allergic diseases.

      Patients: Human tonsil samples will be obtained from less than 30-year-old routine
      tonsillectomy patients after sublingual grass immunotherapy (n=30), nasal live attenuated
      influenza vaccine (n=30 for atopic; and n=30 for non-atopic) and immunotherapy+influenza
      vaccine intervention (n=30). Controls without age limit or intervention (n=580) will also be
      recruited. Of these, age and atopy-matched controls will be selected as comparator groups for
      each intervention trial (n=30 for atopic; and n=30 for non-atopic). Control group will also
      be used for investigation of role of tissues in immune tolerance and chronicity in allergic
      diseases, immunomodulatory effects of respiratory viruses main focus being on human bocavirus
      and human rhinovirus infections, and in the search of new respiratory viruses.

      Design: Study intervention products will be administered openly but the immunology outcomes
      will be analysed blindly.

      Main outcomes: Gene expressions of IFN and T cell related genes will be the main outcomes and
      compared between intervention groups and correlated with the number of allergen extract doses
      or time from nasal influenza vaccination. Systemic immunologic outcomes (in peripheral blood
      mononuclear cells, blood RNA expression profiles, antibodies and cytokines in serum) will
      also be studied. The analyses include immunogenetics, virology, bacteriology and
      sensitization status. Clinical symptom scores will be recorded during the next 12 months from
      the screening visit.

      Anticipated results: We expect that our tonsil approach will offer a new in vivo model for
      the understanding immune tolerance induction and will give new insights to the immunologic
      mechanisms in lymphoid tissue level. We hope to demonstrate that the immunologic effects of
      sublingual pollen immunotherapy can be modified with a nasal live attenuated influenza
      vaccine and thereby it should give basis for other add-on treatments aiming for more
      effective immunotherapy. The influenza virus vaccine is expected to promote Th1 cell
      expression over Th2 cell expression. Since the immunologic outcomes will be correlated to
      clinical efficacy during next influenza and pollen seasons, we hope to understand the
      clinical significance of the immunologic outcomes.

      Innovation and impact: The unique strength of the project is to answer essential questions on
      development of allergen tolerance and a protective vaccine response in a human in vivo
      situation that cannot be answered in other settings. The proposed investigations may
      substantially enlarge our knowledge on the pathogenesis of organ directed allergic and
      non-allergic inflammation in humans, because the experiments will be performed directly with
      disease associated human cells and tissues. We expect that novel genes and pathways of immune
      regulation can be identified in tonsils by a detailed investigation of human immune response
      development to sublingual immunotherapy and influenza vaccine. The transcriptome and
      epigenome of these groups and further analyses of the role of T cells, B cells and innate
      lymphoid cells will provide essential information particularly on differences between atopic
      and non-atopic individuals, and anti-vaccine responses, natural viral infection, chronic
      viral infection, mechanisms of hypertrophic tonsillitis versus recurrent tonsillitis. The
      identification of new immune tolerance and immune activation pathways involved in the
      regulation of tissue cells is expected to provide novel knowledge for many other diseases in
      addition to asthma, because dysregulated immune system activation occurs in various human
      disorders such as cancer, autoimmunity, transplantation rejection and chronic infections.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expressions of interferon and T cell and closely related cytokines and transcription factors in tonsils.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Expressions of IFN-α, IFN-β, IFN-γ, IL-10, IL-13, IL-17, IL-28, IL-29, IL-37, TGF-β, FOXP3, GATA3, RORC2 and Tbet will be analyzed by quantitative real-time PCR.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Timothy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Live attenuated influenza virus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timothy + attenuated influenza virus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention (n=60, 50:50 atopic:non-atopic).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Timothy, Phleum pretense</intervention_name>
    <description>Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .</description>
    <arm_group_label>Live attenuated influenza virus</arm_group_label>
    <arm_group_label>Timothy + attenuated influenza virus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live attenuated influenza virus</intervention_name>
    <description>Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).</description>
    <arm_group_label>Timothy</arm_group_label>
    <arm_group_label>Timothy + attenuated influenza virus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Timothy + attenuated influenza virus</intervention_name>
    <description>Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).</description>
    <arm_group_label>Timothy</arm_group_label>
    <arm_group_label>Live attenuated influenza virus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective tonsillectomy with or without adenotomy according to clinical indication

          -  age &gt;4 and &lt;30 years

          -  written informed consent from the study subject or his/her guardian

          -  Fluenz® will be used for ages &gt;4 and &lt;30 years, i.e. off-label use of ages &gt;18 and &lt;30
             years

        Exclusion Criteria:

          -  systemic anti-inflammatory medication within prior 4 weeks

          -  systemic diseases affecting the immune system e.g. autoimmune diseases, immune complex
             diseases or immune deficiency diseases other than allergy, asthma or atopic dermatitis

          -  malignancy, depression, psychiatric illness or medication; planned vaccination during
             the study period (vaccinations should not be given during study period)

          -  forced expiratory volume in 1 second (FEV1) is under 80% of normal value or asthma is
             in a bad balance for those patients who would participate in the immunotherapy

          -  sublingual grass pollen will not be given for children under the age of 5

          -  additional exclusion criteria for Grazax® include hypersensitivity to any of the
             excipients (gelatin [fish source], mannitol, sodium hydroxide), inflammatory
             conditions in the oral cavity with severe symptoms such as oral lichen planus with
             ulcerations or severe oral mycosis, patients with uncontrolled or severe asthma (in
             adults: FEV1 &lt; 70% of predicted value after adequate pharmacologic treatment, in
             children: FEV1 &lt; 80% of predicted value after adequate pharmacologic treatment)

          -  addition exclusion criteria for Fluenz® include hypersensitivity to the active
             substances, to any of the excipients (sucrose, dibasic potassium phosphate, monobasic
             potassium phosphate, gelatin [porcine, Type A], arginine hydrochloride, monosodium
             glutamate monohydrate, gentamicin [a possible trace residue], eggs or to egg proteins
             [e.g. ovalbumin] and children and adolescents younger than 18 years of age receiving
             salicylate therapy because of the association of Reye's syndrome with salicylates and
             wild-type influenza infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuomas Jartti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Pediatrics, Turku University Hospital, Turku, Finland.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cezmi Akdis, M.D., prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Christine Kühne-Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tuomas Jartti, M.D.</last_name>
    <phone>+358 40 7270 284</phone>
    <email>tuomas.jartti@utu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Varpu Elenius, M.D.</last_name>
    <phone>+358 40 5746 410</phone>
    <email>varkainu@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Otorhinolaryngology, Satakunta Central Hospital</name>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antti Silvoniemi, M.D.</last_name>
      <phone>+358 2 314 4933</phone>
      <email>antti.silvoniemi@utu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tuomo Puhakka, M.D.</last_name>
      <phone>+358 2 313 0626</phone>
      <email>tuomo.puhakka@tyks.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Antti Silvoniemi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirsi Ylitalo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Otorhinolaryngology, Salo Regional Hospital</name>
      <address>
        <city>Salo</city>
        <zip>24130</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Silvoniemi, M.D.</last_name>
      <phone>+358 2 314 4933</phone>
      <email>antti.silvoniemi@utu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tuomo Puhakka, M.D.</last_name>
      <phone>+358 2 313 0626</phone>
      <email>tuomo.puhakka@tyks.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Antti Silvoniemi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Otorhinolaryngology, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuomo Puhakka, M.D.</last_name>
      <phone>+358 2 313 0626</phone>
      <email>tuomo.puhakka@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Antti Silvoniemi, M.D.</last_name>
      <phone>+358 2 314 4933</phone>
      <email>antti.silvoniemi@utu.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Tuomo Puhakka, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Silvoniemi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuomas Jartti, M.D.</last_name>
      <phone>+358 40 7270 284</phone>
      <email>tuomas.jartti@utu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Varpu Elenius, M.D.</last_name>
      <phone>+358 40 5746410</phone>
      <email>varkainu@utu.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Tuomas Jartti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Varpu Elenius, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Saarinen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Kücüksezer UC, Palomares O, Rückert B, Jartti T, Puhakka T, Nandy A, Gemicioğlu B, Fahrner HB, Jung A, Deniz G, Akdis CA, Akdis M. Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood. J Allergy Clin Immunol. 2013 Mar;131(3):875-85. doi: 10.1016/j.jaci.2012.10.051. Epub 2012 Dec 23.</citation>
    <PMID>23265862</PMID>
  </reference>
  <reference>
    <citation>Palomares O, Rückert B, Jartti T, Kücüksezer UC, Puhakka T, Gomez E, Fahrner HB, Speiser A, Jung A, Kwok WW, Kalogjera L, Akdis M, Akdis CA. Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as potential first-line organs of oral tolerance. J Allergy Clin Immunol. 2012 Feb;129(2):510-20, 520.e1-9. doi: 10.1016/j.jaci.2011.09.031. Epub 2011 Nov 3.</citation>
    <PMID>22051696</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Tuomas Jartti</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Timothy</keyword>
  <keyword>Influenza</keyword>
  <keyword>Interferon</keyword>
  <keyword>T cell</keyword>
  <keyword>Tonsil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

